1 – 10 of 16
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years.
(
- Contribution to journal › Article
- 2012
-
Mark
Evaluation of a new immunoassay for cystatin C, based on a double monoclonal principle, in men with normal and impaired renal function
(
- Contribution to journal › Article
- 2011
-
Mark
Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
(
- Contribution to journal › Article
- 2010
-
Mark
Association Between Glomerular Filtration Rate, Free, Total, and Percent Free Prostate-specific Antigen EDITORIAL COMMENT
(
- Contribution to journal › Debate/Note/Editorial
- 2009
-
Mark
Increase in percent free prostate-specific antigen in men with chronic kidney disease.
2009) In Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 24. p.1238-1241(
- Contribution to journal › Article
- 2005
-
Mark
Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.
(
- Contribution to journal › Article
- 2004
-
Mark
Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.
(
- Contribution to journal › Article
- 2003
-
Mark
Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.
(
- Contribution to journal › Article
-
Mark
Serum cystatin C is a more sensitive and more accurate marker of glomerular filtration rate than enzymatic measurements of creatinine in renal transplantation.
(
- Contribution to journal › Article
-
Mark
Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues
(
- Contribution to journal › Article